Sanofi-B (02257) issued an announcement that due to the failure to pass ordinary resolutions 2 (i) and 2 (ii) for the re-election of Dr. David Mark Evans and Dr. Wang Yongxiang as executive directors respectively at the shareholder's annual meeting, Dr. Evans and Dr. Wang have resigned as executive directors in accordance with the revised and restated rules of the company's articles of association, effective from the end of the shareholder's annual meeting. Dr. Evans will remain the head of the group's drug development and collaboration, and Dr. Wang will remain the group's chief manufacturing officer.
According to an announcement released by Sanofi-B (02257), Dr. David Mark Evans and Dr. Wang Yongxiang did not pass ordinary resolutions 2 (i) and 2 (ii) for the re-election as executive directors respectively at the shareholder's annual meeting. Therefore, Dr. Evans and Dr. Wang have resigned as executive directors in accordance with the revised and restated rules of the company's articles of association, effective from the end of the shareholder's annual meeting. Dr. Evans will remain the head of the group's drug development and collaboration, and Dr. Wang will remain the group's chief manufacturing officer.
Since the ordinary resolution 2 (iv) for the re-election of Mr. Hu Fengmao as independent non-executive director did not pass at the shareholder's annual meeting, Mr. Hu has resigned as an independent non-executive director in accordance with the rules of the organization's articles of association, effective from the end of the shareholder's annual meeting. After Mr. Hu's resignation, he will no longer be a member of the company's audit committee and the chairman and members of the company's nomination committee.